Results 1 to 10 of about 44,703 (257)
The BRAF V600E/MEK/ERK/METTL3 positive feedback loop regulates autophagy and promotes stemness and invasiveness in glioblastoma via m6A modification [PDF]
Background Epithelioid glioblastoma (GBM) is characterized by its highly aggressive behavior and the presence of the BRAF V600E mutation. However, the impact and underlying mechanisms of the BRAF V600E mutation on GBM stemness and invasiveness are ...
Yuan Xie +17 more
doaj +2 more sources
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated [PDF]
Background Most mutations in melanoma affect one critical amino acid on BRAF gene, resulting in the V600E substitution. Patient management is often based on the use of specific inhibitors targeting this mutation.
Muna Al Hashmi +16 more
doaj +5 more sources
BRAF/V600E mutation and other cell growth/growth-control mechanisms are involved in naevogenesis and melanomagenesis. Immunoexpression of BRAF/V600E and other molecules (p16, phosphatase and tensin homologue (PTEN), Ki67, hTERT and Cav3.1 and 3.2 calcium
Sara Moreno +16 more
doaj +1 more source
BRAFV600E-Negative Hairy Cell Leukaemia [PDF]
Since the initial report of theBRAFV600E mutation in hairy cell leukemia, numerous investigators have demonstrated the presence of this activating mutation in nearly all cases of this disease. A case of hairy cell leukemia is documented with a classical clinical, morphological, immunophenotypic, and cytochemical profile in which theBRAFV600E was not ...
Stephen E. Langabeer +4 more
openaire +6 more sources
BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease. [PDF]
Erdheim-Chester disease (ECD) is a rare histiocytosis with a high prevalence of BRAF V600E mutation (>50% of patients). Patients with BRAF-mutant ECD can respond to BRAF inhibitors.
Cabrilo, Goran +12 more
core +11 more sources
Background The effects of BRAF non-V600E and BRAF V600E on the outcomes and the molecular characteristics of adult glioma patients are unknown and need to be explored, although BRAF V600E has been extensively studied in pediatric glioma.
Wei Wang +4 more
doaj +1 more source
Background: The B-type rafkinase (BRAF) V600E gene mutation plays an important role in the pathogenesis, diagnosis, and prognosis of thyroid carcinoma. This study was conducted to investigate the rate of the BRAF V600E mutation, the relationships between
Tri Bui Dang Minh +15 more
doaj +1 more source
BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas [PDF]
Low-grade gliomas (LGG) are the most common central nervous system tumors in children. Prognosis depends on complete surgical resection. For patients not amenable of gross total resection (GTR) new approaches are needed. The BRAF mutation V600E is critical for the pathogenesis of pediatric gliomas and specific inhibitors of the mutated protein, such as
Francesca Del Bufalo +11 more
openaire +3 more sources
Aim – This study aimed to analyze the association between B-Raf proto-oncogene, serine/threonine kinase (BRAF) V600E and tumor size, lymph node, and distant metastasis (TNM) status on patients with papillary thyroid carcinoma. Material and Methods – This
Edmond Rukmana Wikanta +4 more
doaj +1 more source
Lkb1 loss promotes tumor progression of BRAF(V600E)-induced lung adenomas. [PDF]
Aberrant activation of MAP kinase signaling pathway and loss of tumor suppressor LKB1 have been implicated in lung cancer development and progression. Although oncogenic KRAS mutations are frequent, BRAF mutations (BRAF(V600E)) are found in 3% of human ...
Elena González-Sánchez +8 more
doaj +1 more source

